Inventiva has made its preparatory documents available for a crucial Combined General Meeting on June 30, 2026. This announcement reflects the company’s commitment to providing timely updates on its clinical-stage biopharmaceutical work focusing on MASH therapy.

Kaldvik AS convened an extraordinary general meeting in Frøya on June 19, 2025, drawing significant shareholder participation with over 62% in attendance.